Mumbai - Wockhardt Hospitals, Mira Road recently managed a rare and challenging cardiac case where “silent” venous occlusion ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

Large vessel occlusion thrombectomy procedures are being used in medium vessel occlusions, leading to changes in device ...

A new study published in the Journal of American Medical Association showed that subcutaneous nitroglycerin demonstrated ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

Medanta Medicity doctors said the case highlights the expanding role of image-guided interventions in managing high-flow AVMs, especially during high-risk surgeries.

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

The FDA also approved an every 4 week dosing regimen across all approved indications for patients who may not maintain a response on extended dosing intervals following successful initial treatment.

Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across ...

The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...

The approvals come as a pleasant surprise for Regeneron, analysts say, helping bolster the overall product profile of high-dose Eylea despite outstanding manufacturing concerns.